Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07159412

Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis

A Randomized, Double-Blind, Placebo-Controlled Trial of Huazhi Rougan Granule Combined With High-Dose Dual Therapy for Helicobacter Pylori Infection Complicated With Metabolic-associated Steatohepatitis (Dampness-Heat Accumulation Syndrome)

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
286 (estimated)
Sponsor
Nanjing First Hospital, Nanjing Medical University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study employed a double-blind, randomized, placebo-controlled design. Eligible treatment-naïve patients with Helicobacter pylori (Hp) infection complicated by metabolic-associated steatohepatitis (MASH) (dampness-heat accumulation syndrome) were enrolled and randomly assigned to either the experimental group or the placebo control group. Both groups received a 2-week Hp eradication regimen consisting of vonoprazan (20 mg twice daily) and amoxicillin (1000 mg three times daily). The experimental group additionally received active Huazhi Rougan Granule (taken orally three times daily, one sachet each time, with a 6-day medication followed by a 1-day drug holiday per cycle), while the placebo control group received an identical matching placebo on the same schedule. The study aims to evaluate the synergistic therapeutic efficacy of Huazhi Rougan Granule in combination with the vonoprazan-amoxicillin dual therapy.

Conditions

Interventions

TypeNameDescription
DRUGVonoprazan-amoxicillin combined with Huazhi Rougan GranuleVonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule
DRUGVonoprazan-amoxicillin combined with Huazhi Rougan Granule placeboVonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule placebo

Timeline

Start date
2025-08-31
Primary completion
2026-08-31
Completion
2027-08-31
First posted
2025-09-08
Last updated
2025-09-08

Source: ClinicalTrials.gov record NCT07159412. Inclusion in this directory is not an endorsement.